Secukinumab and Apremilast Combination Therapy for Recalcitrant Psoriasis

To claim CME credit please complete the following steps:

  1. Review the CME information below.
  2. Read the article. To read the full text article, you must be Professional Member of the National Psoriasis Foundation. Not a member, Sign Up Now. 
  3. Achieve a 70% or higher on the online case based post test. To do so, login, and select Take Course at right.
  4. Complete the online evaluation 

If you do not yet have an account with the National Psoriasis Foundation, please click here to create a new account prior to taking this course. Thank you! 

CME Information

The National Psoriasis Foundation CME activities are based on identified professional practice gaps. The professional practice gaps are defined as the differences between the currently observed health care performance/outcomes and those potentially achievable. The National Psoriasis Foundation utilizes data from a variety of methods to identify professional practice gaps including: annual patient data from our constituents; advice and research from authorities in the dermatology and rheumatology specialties, the NPF Medical Board, faculty or staff; discussion in CME Education meetings; data from peer-reviewed journals, government sources, environmental scans, legislative, and regulatory or organizational changes affecting patient care and many more.

Link to the articleSecukinumab and Apremilast Combination Therapy for Recalcitrant Psoriasis

Accreditation

The National Psoriasis Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA PRA Designation

The National Psoriasis Foundation designates this Journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credits ™.  Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclaimer

The National Psoriasis Foundation does not endorse or recommend any treatment regimens, diets, medications or products.  The National Psoriasis Foundation is solely responsible for all content.

Conflict of Interest Resolution

In accordance with the ACCME Standards for Commercial Support of CME, the National Psoriasis Foundation has implemented mechanisms, prior to the planning and implementation of the Journal-based CME activity, to identify and resolve conflicts of interest for all individuals in a position to control the content of this Journal- based CME activity.

Target Audience

Dermatologists, rheumatologists, primary care physicians, and allied health providers

Learning Objectives

After completing this learning activity, the learner should be able to understand apremilast’s mechanism of action and side effect profile, along with the concept that treating psoriatic arthritis can be different from treating psoriasis.

Questions? Contact us at medevents@psoriasis.org 

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™

    Accreditation

    This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education through the joint providership of Oregon Health & Science University (OHSU) and the National Psoriasis Foundation. OHSU is accredited by the ACCME to provide CME for physicians.

    Credit

    OHSU School of Medicine, Division of CME, designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.00 CE
Course opens: 
03/20/2017
Course expires: 
03/20/2019
Cost:
$0.00
Rating: 
0

Accreditation Period

Course opens: 
03/20/2017
Course expires: 
03/20/2019

Price

Cost:
$0.00
Please login to take this course.